Close-up of stacked petri dishes with yellow agar medium, showing bacterial colonies growing on the surface.

Uticaj probioitika na imuni sistem

Gastrointestinalni trakt čini značajan deo odbrambenog imunog sistema. U stvari, 80% imunog sistema nalazi se u crevima.

<

Uticaj probiotika na imuni sistem

Uravnotežena gastrointestinalna flora pojačava imuni sistem, doprinosi opštem dobrom zdravlju i unapređuje ga.

Dva klinička ispitivanja sa L. reuteri Protectis (BioGaia) pokazala su da ovaj preparat ima pozitivne efekte u sprečavanju infekcija.

Kao dodatak ishrani, probiotik BioGaia u mnogome ima pozitivan efekat na pojavu običnih infekcija kod dece u obdaništima i može da poboljša zdravlje zaposlenih, tako što se smanjuje broj dana provedenih na bolovanju uzrokovano respiratornim ili gastrointestinalnim infekcijama.

BioGaia Protectis ojačava imuni sistem

•U interakciji sa imunim sistemom u GI traktu

• Usklađuje odgovor imunog sistema pomoću citokina i hemokina u tkivima koja se nalaze u distalnom delu creva

• Ubrzava odgovor imunog sistema

• Održava zdravlje kod dece i odraslih

• Može da smanji rizik od respiratorne alergije i astme u kasnijim godinama života

 

Uravnotežena gastrointestinalna flora doprinosi opštem dobrom zdravlju i unapređuje ga.

 

BioGaia®  probiotske kapi i tablete

Pokazalo se da Limosilactobacillus (Lactobacillus) reuteri Protectis održava ravnotežu bakterija u digestivnom traktu i pomaže njegovom funkcionisanju, a čuva i odbrambeni sistem organizma.

 

BioGaia® preporučena doza

1 tableta za žvakanje ili 5 kapi dnevno

Comparison of two probiotic agents

Effect of a probiotic infant formula on infections in child care centres.

Weizman Z, Asli G, Alsheikh A. (2005) Pediatrics 115:5-9.
Health protection with BioGaia Protectis in children.

Results

L. reuteri significantly reduced

  • days with fever
  • episodes and days with diarrhoea
  • need to consult a doctor and need of antibiotics
  • absence from day care

Conclusions

  • Occurrence of number of febrile episodes and episodes of gastrointestinal infections were statistically less frequent in the probiotic group
  • L. reuteri (BioGaia) had a significantly superior effect compared to B. lactis
  • Significantly fewer doctor visits, fewer use of antibiotics and fewer absent days from day care

Facts

  • Prospective, randomized, placebo controlled study
  • 201 healthy children, aged 4–10 months, were studied for 12 weeks in three different groups:
  • They were given formula with L. reuteri ATCC 55730 (BioGaia) or Bifidobacterium lactis Bb-12, or formula without probiotics (control)

Randomizovana, duplo slepa, placebo kontrolisana klinička studija

Unapređenje zdravlja na radnom mestu korišćenjem probiotika Limosilactobacillus (Lactobacillus) reuteri: Randomizirana, dvostruko slepa, placebo kontrolisana studija

Tubelius et al., Environ Health 4:25 (2005). Zaštita zdravlja odraslih osoba pomoću preparata Biogaia.

Results

  • Reduced sick days at home with short term
  • gastro-intestinal or respiratory illness
  • The frequency of sick days of ordinary workdays was 0.9% in the placebo group vs. 0.4% in the L. reuteri group (p<0.01)
  • L. reuteri: <1 sick day /individual and year
  • Placebo: 3 sick days /individual and year

Conclusions

  • Daily supplementation with the probiotic Limosilactobacillus reuteri ATCC 55730 (BioGaia) could reduce the incidence of common infections and thereby reduce short-term sick leave at a major Swedish workplace.
  • Effect pronounced in shift workers

Facts

  • Randomised, double blind, placebo-controlled study
  • 181 healthy company employees , received once daily over 3 months to use a probiotic drinking straw containing 10^8 CFU of L. reuteri (Bio- Gaia) or an identical placebo drinking straw, together with at least 100 ml liquid and completed a diary on symptoms of gastrointestinal infection or upper respiratory tract infection (common cold), duration of symptoms and number of days away from work due to such symptoms.
  • L. reuteri (n=94) or placebo (n=87).